Replies to post #1715 on Spectrum Pharmaceutecals Inc (SPPI)

[Ville7]

As antihama is looking forward to the breast cancer update of the korean study at ESMO 2017 i want to add one thought regarding the exon 20 mutation trial: pozitinib shrank tumors in vivo 85% for EGFR exon 20 and 60% for HER exon 20 mutation. So MD Anderson started with more promising EGFR exon 20 part. Recently they doubled the trial to include HER exon 20 mutations. So just think about it and use a little logic: They must have seen enough activity in EGFR exon 20 mutations otherwise they wouldn't have started the second cohort with HER exon 20 mutations.